983 resultados para ARM Linux
Resumo:
BACKGROUND: In uveal melanoma (UM) with metastatic disease limited to the liver, the effect of an intrahepatic treatment on survival is unknown. We investigated prospectively the efficacy and toxicity of hepatic intra-arterial (HIA) versus systemic (IV) fotemustine in patients with liver metastases from UM. PATIENTS AND METHODS: Patients were randomly assigned to receive either IV or HIA fotemustine at 100 mg/m(2) on days 1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance. Primary end point was overall survival (OS). Response rate (RR), progression-free survival (PFS) and safety were secondary end points. RESULTS: Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis. A total of 155 patients died and 16 were still alive [median follow-up 1.6 years (range 0.25-6 years)]. HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79-1.50, log-rank P = 0.59. However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45-0.84, log-rank P = 0.002). The 1-year PFS rate was 24% in the HIA arm versus 8% in the IV arm. An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%). In the IV arm, the most frequent grade ≥3 toxicity was thrombocytopenia (42.1%) and neutropenia (62.6%), compared with 21.2% and 28.7% in the HIA arm. The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths. CONCLUSION: HIA treatment with fotemustine did not translate into an improved OS compared with IV treatment, despite better RR and PFS. Intrahepatic treatment should still be considered as experimental. EUDRACT NUMBER AND CLINICALTRIALSGOV IDENTIFIER: 2004-002245-12 and NCT00110123.
Resumo:
El proyecto consiste en un conjunto de cuatro tipos de motas cuya clasificación viene determinada por el área que controlan y un terminal central ejecutando Linux que ofrecerá la posibilidad de consultas vía WorldWideWeb a través del protocolo de hipertexto.
Resumo:
Proyecto que pretende diseñar e implementar la infraestructura necesaria para implantar, administrar remotamente y monitorizar servidores perimetrales Linux diseñados para estar ubicados en zona desmilitarizada. La idea a desenvolver es la de crear un producto paquetizado y estable de software y servicio.
Resumo:
Aquest treball de final de carrera està inclòs dins la branca Plataforma GNU/Linux. La voluntat és demostrar que el programari lliure està a l'alçada del programari propietari també en el vessant empresarial. OpenERP és un programa modern de gestió empresarial, sota llicència AGPL, que inclou CRM, HR, vendes, comptabilitat, producció, inventari, gestió de projectes,... És una solució integral de l'empresa gràcies a la flexibilitat i quantitat de mòduls publicats, permetent adaptar-los o modificar-los en cas de necessitat. Està escrit en Python i basat en OpenObject. Té com a característiques principals que és escalable, modulable i intuïtiu. L'objectiu del treball és crear i adaptar OpenERP a un cas concret: la gestoria Fiscalfàcil. Aprofitant tot el potencial d'aquest programa i estudiant les necessitats d'aquesta empresa, crearem un LiveCD amb un OpenERP amb tots els mòduls instal·lats i configurats perquè estigui a punt per treballar.
Resumo:
El plantejament d'aquest projecte sorgeix de l'interès en l'aplicació pràctica del software lliure i en especial de les eines GNU/LINUX en un escenari de negoci real, amb la finalitat d'aprofitar els beneficis que aporten, tant per la varietat de solucions en les que contribueix, com per l'estalvi que suposa a nivell econòmic. Aquest treball vol reunir, en un únic document, la informació necessària per a la posterior implementació de software lliure en la totalitat del sistema informàtic d'una empresa, i més concretament, en una empresa que desenvolupi un negoci de tipus cibercafè.
Resumo:
Aquest memoria descriu els fonaments teòrics i la funcionalitat d'una aplicació per a cifrar arxius i directoris utilitzant la norma PKCS#5 dels laboratoris RSA, a més d'una modificació de la norma (algorisme TripelDES) per a aconseguir cifres més fortes.
Resumo:
BACKGROUND: Acute treatment of ischemic stroke patients presenting more than eight-hours after symptom onset remains limited and largely unproven. Partial aortic occlusion using the NeuroFlo catheter can augment cerebral perfusion in animals. We investigated the safety and feasibility of employing this novel catheter to treat ischemic stroke patients eight-hours to 24 h following symptom onset. METHODS: A multicenter, single-arm trial enrolled ischemic stroke patients at nine international academic medical centers. Eligibility included age 18-85 years old, National Institutes of Health stroke scale (NIHSS) score between four and 20, within eight-hours to 24 h after symptom onset, and perfusion-diffusion mismatch confirmed by magnetic resonance imaging. The primary outcome was all adverse events occurring from baseline to 30 days posttreatment. Secondary outcomes included stroke severity on neurological indices through 90 days. This study is registered with ClinicalTrials.gov, number NCT00436592. RESULTS: A total of 26 patients were enrolled. Of these, 25 received treatment (one excluded due to aortic morphology); five (20%) died. Favorable neurological outcome at 90 days (modified Rankin score 0-2 vs. 3-6) was associated with lower baseline NIHSS (P < 0·001) and with longer duration from symptom discovery to treatment. There were no symptomatic intracranial hemorrhages or parenchymal hematomas. Asymptomatic intracranial hemorrhage was visible on computed tomography in 32% and only on microbleed in another 20%. CONCLUSIONS: Partial aortic occlusion using the NeuroFlo catheter, a novel collateral therapeutic strategy, appears safe and feasible in stroke patients eight-hours to 24 h after symptom onset.
Resumo:
Human immunodeficiency virus (HIV-1) has become an important risk factor for human papillomavirus (HPV) infection and the development of HPV associated lesions in the female genital tract. HIV-1 may also increase the oncogenicity of high risk HPV types and the activation of low risk types. The Center for Disease Control and Prevention declared invasive cervical cancer an acquired immunodeficience virus (AIDS) defining illness in HIV positive women. Furthermore, cervical cancer happens to be the second most common female cancer worldwide. The host's local immune response plays a critical factor in controlling these conditions, as well as in changes in the number of professional antigen-presenting cells, cytokine, and MHC molecules expression. Also, the production of cytokines may determine which arm of the immune response will be stimulated and may influence the magnitude of immune protection. Although there are many studies describing the inflammatory response in HPV infection, few data are available to demonstrate the influence of the HIV infection and several questions regarding the cervical immune response are still unknown. In this review we present a brief account of the current understanding of HIV/HPV co-infection, emphasizing cervical immune response.
Resumo:
Antiretroviral resistance mutations (ARM) are one of the major obstacles for pharmacological human immunodeficiency virus (HIV) suppression. Plasma HIV-1 RNA from 306 patients on antiretroviral therapy with virological failure was analyzed, most of them (60%) exposed to three or more regimens, and 28% of them have started therapy before 1997. The most common regimens in use at the time of genotype testing were AZT/3TC/nelfinavir, 3TC/D4T/nelfinavir and AZT/3TC/efavirenz. The majority of ARM occurred at protease (PR) gene at residue L90 (41%) and V82 (25%); at reverse transcriptase (RT) gene, mutations at residue M184 (V/I) were observed in 64%. One or more thymidine analogue mutations were detected in 73%. The number of ARM at PR gene increased from a mean of four mutations per patient who showed virological failure at the first ARV regimens to six mutations per patient exposed to six or more regimens; similar trend in RT was also observed. No differences in ARM at principal codon to the three drug classes for HIV-1 clades B or F were observed, but some polymorphisms in secondary codons showed significant differences. Strategies to improve the cost effectiveness of drug therapy and to optimize the sequencing and the rescue therapy are the major health priorities.
Resumo:
Simulium cauchense Floch & Abonnenc and Simulium quadrifidum Lutz are widely distributed in the Amazon region and are morphologically similar at the larval and pupal stages. Chromosomally, these species are readily distinguished by the position of the nucleolar organizer, which is in the short arm of chromosome I in S. cauchense and in the long arm of chromosomes III in S. quadrifidum. They also differ by three fixed inversions. Sex chromosomes are undifferentiated in both species. Chromosomal resolution of the two species allowed us to evaluate four structural features previously used as diagnostic aids at the larval stage. Characters that distinguish larvae of the two species are the number of branches and branching patterns of the dorsal abdominal setae and the dark band on each primary fan. Branching patterns of the gill histoblasts were often diagnostic, with S. quadrifidum exhibiting more proximal branching and S. cauchense more distal branching. Sites where both species occurred sometimes had larvae with one petiole branching proximally and the other distally; in these cases examination of the chromosomes permitted assignment of the specimen to species. Pigmentation patterns of larvae, on the other hand, are highly variable. Color typically is sex linked in both species.
Resumo:
L'objectiu d'aquest projecte és estudiar i implementar una solució segura de connectivitat sense fil a la infraestructura actual aprofitant al màxim tots els sistemes ja implementats, de manera que no pateixin greus canvis estructurals.
Resumo:
Projecte denominat Mistelix, una eina d'autoria de DVD en codi obert per a sistemes GNU / Linux.
Resumo:
OBJECTIVE: To describe the clinical and molecular genetic findings in 2 carriers of Duchenne muscular dystrophy (DMD) who exhibited marked hemiatrophy. Duchenne muscular dystrophy is an X-linked disorder in which affected male patients harbor mutations in the dystrophin gene. Female patients with heterozygous mutations may be manifesting carriers. DESIGN: Case study. SETTING: Neurology clinic. PATIENTS: Two manifesting carriers of DMD. INTERVENTIONS: Clinical and radiologic examinations along with histologic and molecular investigations. RESULTS: Both patients had marked right-sided hemiatrophy on examination with radiologic evidence of muscle atrophy and fatty replacement on the affected side. In each case, histologic analysis revealed a reduction in dystrophin staining on the right side. Genetic analysis of the dystrophin gene revealed a tandem exonic duplication in patient 1 and a multiexonic deletion in patient 2 with no further point mutations identified on the other chromosome. CONCLUSIONS: Marked hemiatrophy can occur in DMD manifesting carriers. This is likely to result from a combination of skewed X-inactivation and somatic mosaicism.
Resumo:
Aquest projecte estudia el problema de l'extracció i la visualització de manera entenedora de la informació pública més rellevant d'una adreça IP, tot i que no aborda els problemes relacionats amb la informació insuficient perquè pertanyen a un àmbit de recerca diferent.
Resumo:
Aquest treball ha de permetre a l'enginyer encarregat d'iniciar un procés de selecció d'una aplicació de gestió integral i de formar part de la futura implementació d'un sistema SAP R/3, adquirir els coneixements necessaris per a poder iniciar la implementació coneixent les possibilitats i les limitacions del sistema i l'estructura seguida en la implementació, a més dels recursos que hauran d?assignar-s?hi.